Free Trial
NASDAQ:TXMD

TherapeuticsMD Q2 2025 Earnings Report

TherapeuticsMD logo
$1.09 -0.02 (-1.36%)
As of 01:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TherapeuticsMD EPS Results

Actual EPS
$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TherapeuticsMD Revenue Results

Actual Revenue
$0.95 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TherapeuticsMD Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

TherapeuticsMD Earnings Headlines

TherapeuticsMD Reports Q2 2025 Financial Results
TherapeuticsMD: Q2 Earnings Snapshot
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
TherapeuticsMD Announces Second Quarter 2025 Financial Results
TherapeuticsMD (NASDAQ:TXMD) Stock Price Up 0.5% - Should You Buy?
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

View TherapeuticsMD Profile

More Earnings Resources from MarketBeat